Literature DB >> 12646003

Quantitative comparison of functional screening by measuring intracellular Ca2+ with radioligand binding at recombinant human dopamine receptors.

Matthias U Kassack1.   

Abstract

The purpose of this study was to test whether screening at dopamine receptors performed with a recently described functional assay for G-protein coupled receptors (GPCRs) provides data that correlate significantly with radioligand binding data in the literature, thus possibly allowing researchers to replace radioligand binding with nonradioactive functional screening. Human dopamine receptors hD1 and hD2L (representing Gs [hD1] or Gi [hD2L] coupled GPCRs) were recombinantly expressed in human embryonic kidney (HEK293) cells. Cells were loaded with Oregon Green 488 BAPTA-1/AM and evenly distributed in 384 well plates. Seventeen test compounds were screened for agonistic activity by injection into the cell suspension and monitoringH of intracellular Ca2+ with a fluorescence microplate reader. Then, standard agonists (100nM SKF38393 for hD1, 30nM quinpirole for hD2L) were injected into wells preincubated with test compounds (screening for antagonism). Injection of various agonists resulted in a concentration-dependent increase in fluorescence. Further, preincubation of antagonists with dopamine receptor expressing cells inhibits concentration-dependent the agonist-induced increase in fluorescence. Calculated apparent functional Ki values correlate with radioligand binding data in the literature (r2 = 0.7796 for D1, r2 = 0.7743 for D2). The correlation between apparent functional Ki values and radioligand binding data for the 17 tested compounds suggests that screening of test compounds at dopamine receptors with the functional Ca2+ assay can replace radioligand binding studies. Furthermore, besides apparent Ki values, information about agonistic or antagonistic properties of a test compound can be obtained with the functional Ca2+ assay.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12646003      PMCID: PMC2751320          DOI: 10.1208/ps040431

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  45 in total

Review 1.  Localization and function of the D3 dopamine receptor.

Authors:  P Sokoloff; B Giros; M P Martres; M Andrieux; R Besancon; C Pilon; M L Bouthenet; E Souil; J C Schwartz
Journal:  Arzneimittelforschung       Date:  1992-02

2.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.

Authors:  R K Sunahara; H C Guan; B F O'Dowd; P Seeman; L G Laurier; G Ng; S R George; J Torchia; H H Van Tol; H B Niznik
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

3.  Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride.

Authors:  H Hall; L Farde; G Sedvall
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 4.  Practical aspects of measuring [Ca2+] with fluorescent indicators.

Authors:  J P Kao
Journal:  Methods Cell Biol       Date:  1994       Impact factor: 1.441

5.  Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors.

Authors:  B Gomez-Mancilla; R Boucher; C Gagnon; T Di Paolo; R Markstein; P J Bédard
Journal:  Mov Disord       Date:  1993-04       Impact factor: 10.338

Review 6.  Dopamine receptor pharmacology.

Authors:  P Seeman; H H Van Tol
Journal:  Trends Pharmacol Sci       Date:  1994-07       Impact factor: 14.819

7.  A functional test identifies dopamine agonists selective for D3 versus D2 receptors.

Authors:  F Sautel; N Griffon; D Lévesque; C Pilon; J C Schwartz; P Sokoloff
Journal:  Neuroreport       Date:  1995-01-26       Impact factor: 1.837

8.  Expression and pharmacological characterization of the human D3 dopamine receptor.

Authors:  S B Freedman; S Patel; R Marwood; F Emms; G R Seabrook; M R Knowles; G McAllister
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

9.  Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.

Authors:  B Levant; D E Grigoriadis; E B DeSouza
Journal:  J Pharmacol Exp Ther       Date:  1992-09       Impact factor: 4.030

10.  Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand.

Authors:  P Seeman; H H Van Tol
Journal:  Eur J Pharmacol       Date:  1995-10-15       Impact factor: 4.432

View more
  1 in total

1.  Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis.

Authors:  Alexandra Hamacher; Mathias Weigt; Michael Wiese; Barbara Hoefgen; Jochen Lehmann; Matthias U Kassack
Journal:  BMC Pharmacol       Date:  2006-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.